Venous Wall of Patients with Chronic Venous Disease Exhibits a Glycolytic Phenotype

Chronic venous disease (CVeD) is a rising medical condition characterized by a broad spectrum of disorders in the venous system. Varicose veins (VVs) represent a frequent clinical manifestation of CVeD, particularly in the lower limbs. Prior histopathological studies have defined a set of alteration...

Full description

Saved in:
Bibliographic Details
Published inJournal of personalized medicine Vol. 12; no. 10; p. 1642
Main Authors Fraile-Martinez, Oscar, García-Montero, Cielo, Alvarez-Mon, Miguel Ángel, Gomez-Lahoz, Ana M., Monserrat, Jorge, Llavero-Valero, Maria, Ruiz-Grande, Fernando, Coca, Santiago, Alvarez-Mon, Melchor, Buján, Julia, García-Honduvilla, Natalio, Saz, Jose V., Ortega, Miguel A.
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 03.10.2022
MDPI
Subjects
Antibodies
Dehydrogenases
Gene expression
Glucose
Glucose transporter
Glycolysis
Hypertension
Hypoxia
Kinases
Laboratories
Metabolism
Patients
Phenotypes
Precision medicine
Protein expression
Protein transport
Statistical analysis
Veins & arteries
Womens health
United States > US
Online AccessGet full text

Cover

More Information
Summary:Chronic venous disease (CVeD) is a rising medical condition characterized by a broad spectrum of disorders in the venous system. Varicose veins (VVs) represent a frequent clinical manifestation of CVeD, particularly in the lower limbs. Prior histopathological studies have defined a set of alterations observed in the venous wall of patients with VVs, affecting their structure and behavior. Metabolic changes in the veins appear to be a critical biological mechanism aiding our understanding of the pathogenesis of CVeD. In this sense, previous studies have identified a potential role of a glycolytic phenotype in the development of different vascular disorders; however, its precise role in CVeD remains to be fully explored. Thus, the aim of the present study was to analyze the gene and protein expression of glucose transporter 1 (GLUT-1) and the glycolytic enzymes PGK-1, ALD, GA3PDH and LDH in the VVs of patients with CVeD (n = 35) in comparison to those expressed in healthy subjects. Our results display enhanced gene and protein expression of GLUT-1, PGK-1, ALD, GA3PDH and LDH in patients with CVeD, suggesting a glycolytic switch of the venous tissue. Greater understanding of the impact of this glycolytic switch in patients with CVeD is required to define a possible pathophysiological role or therapeutic implications of these changes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm12101642